Recently, due to its high effectiveness and tolerability, the treatment of chronic hepatitis B with entecavir became a standard practice. However, limited knowledge is currently available about its pharmacokinetic behaviour and intracellular disposition. Recently, our group reported an inverse correlation between entecavir plasma concentrations and the HBV DNA decay at the first and third month of treatment, respectively. In this paper we investigated the penetration of entecavir in peripheral blood mononuclear cells (PBMC) and in plasma, in order to evaluate the relationship between intracellular penetration and response, in a cohort of naive patients with hepatitis B e antigen (HBeAg)-negative CHB.

中文翻译：

---

恩替卡韦在HBeAg阴性慢性乙型肝炎治疗期间在外周血单个核细胞中的渗透与HBV DNA衰减之间的相关性。

近来，由于其高效和耐受性，恩替卡韦治疗慢性乙型肝炎已成为标准做法。但是，目前关于其药代动力学行为和细胞内处置的知识有限。最近，我们的小组报告恩替卡韦血浆浓度与治疗第一个月和第三个月的HBV DNA衰减之间呈负相关。在本文中，我们研究了恩替卡韦在未感染乙肝e抗原（HBeAg）的初治患者中的外周血单个核细胞（PBMC）和血浆中的渗透，以评估细胞内渗透与反应之间的关系。 。